Applications published 13 July 2011

Published: 16-Aug-2011

Selected patent applications from the weekly European Patents Bulletin


  • Tetracycline compounds for the treatment of rheumatoid arthritis and related methods of treatment
    Paratek Pharmaceuticals 2341771*

  • Synthesis of decitabine
    ScinoPharm Taiwan 2341772*

  • Pharmaceutical compsns of atorvastatin
    Merck Sharp & Dohme 2341773*

  • Treatment of neuroblastoma with multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamptothecin
    Enzon Pharmaceuticals 2341774*

  • Inhibitors of janus kinases
    Merck 2341775*

  • Compounds, compsns and methods comprising imidazole and triazole derivatives
    Institute for OneWorld Health 2341776*

  • Antimicrobial oxazolidinone, hydantoin and imidazolidinone compsns
    NovaBay Pharmaceuticals 2341777*

  • Pharmaceutical compsn
    R-Tech Ueno 2341894*

  • Hyaluronic acid cryogel – compsns, uses, processes for manufacturing
    Burdica Biomed 2341895*

  • Lipid pellets with enhanced taste-masking
    Breitkreutz Jörg 2341896*

  • Nanoparticles for immunotherapy
    Ecole Polytechnique Fédérale de Lausanne 2341897*

  • Stable solid formulations of GC0-C receptor agonist polypeptides suitable for oral administration
    Ironwood Pharmaceuticals 2341898*

  • pH-dependent controlled release pharmaceutical opioid compsn with resistance against the influence of ethanol
    Evonik Röhm 2341899*

  • A medicinal product and treatment
    AFT Pharmaceuticals 2341900*

  • A polysaccharide capsule enclosing a fatty acid oil-containing emulsion
    Pronova BioPharma Norge 2341901*

  • Glucoside derivatives and uses thereof as SGLT inhibitors
    Novartis 2341902*

  • Cannabinoids for use in treating cognitive impairment and dementia
    Bionorica Research 2341903*

  • Methods for treatment of multiple sclerosis
    Fibrogen 2341904*

  • Sustained release formulations using non-aqueous carriers
    Amylin Pharmaceuticals 2341905*

  • Haematopoietic protection against ionising radiation using selective cyclin-dependent kinase 4/6 inhibitors
    The Univ. of North Carolina at Chapel Hill 2341906*

  • Synergistic combinations of a macrocyclic inhibitor of HCV and a nucleoside
    Ortho-McNeil-Janssen Pharmaceuticals 2341907*

  • Individual 5-fluorouracile dose optimisation in folfiri treatment
    Centre Regional de Lutte Contre le Cancer d-Angers; Universite d’Angers 2341908*

  • Nocel substituted azabenzoxazoles
    Merck Sharp & Dohme 2341909*

  • Immediate release dosage forms of sodium oxybate
    Jazz Pharmaceuticals 2341910*

  • Haematopoietic protection against chemotherapeutic compounds using cyclin-dependent kinase 4/6 inhibitors
    The University of North Carolina at Chapel Hill 2341911*

  • Method of treatment of attention deficit/hyperactivity disorder (ADHD)
    Supernus Pharmaceuticals 2341912*

  • Method of enhancing TGF-beta signalling
    Saint Louis University; Auxagen 2341913*

  • Modulation of toll-like receptor 3 expression by antisense oligonucleotides
    Idera Pharmaceuticals 2341914*

  • Phosphorylated dendrimers as antiinflammatory drugs
    Centre National de la Recherche Scientifique; Institut National e la Santé et de la Recherche Medicale 2341915*

  • Colostrum compsn
    Nanoko 2341916*

  • A topical compsn comprising extracts of A. indica and M. charantia or S. indicum
    Unilever 2341917*

  • Herbal formulations
    Life Biotech Medical Research 2341918*

  • CGRP receptor antagonists
    Merck Sharp & Dohme 2341919*

  • Antimicrobial peptides
    Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt 2341920*

  • Antimicrobial peptides
    Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt 2341921*

  • Complement proteins
    The Provost, Fellows and Scholars of the College of the Holy and Undivided Trinity of Queen Elizabeth near Dublin 2341922*

  • Pharmaceutical compsn comprising coenzyme Q10
    Sharma, Saumya’ Thakur, Srinath; Setty, Swati; Kulkarni, Rajesh; Kulkarni, Shirishkumar 2341923*

  • Methods of treating hepatitis C virus infection
    The J David Gladstone Institutes 2341924*

  • Compsn of thrombolytic agent and antithrombosis and also its production method
    Pt Dexa Medica 2341925*

  • Method for purifying protein complexes
    Immunobiology 2341926*

  • Novel immunotherapy against several tumours including neuronal and brain tumours
    Immatics Biotechnologies 2341927*

  • Mycobacterium tuberculosis vaccine
    University of Zürich 2341928*

  • Compsns and methods related to bacterial EAP, EMP, and/or ADSA proteins
    University of Chicago 2341929*

  • Outer membrane vesicle prime-protein boost vaccine
    Health Protection Agency 2341930*

  • Vaccine compsn for use against influenza
    Wittycell; Serra, Vincent 2341931*

  • High-energy pulsed electric field vaccine adjuvants
    OOO “Npt Mpb Gormezis” 2341932*

  • Lipidated imidazoquinoline derivatives
    GlaxoSmithKline Biologicals 2341933*

  • Methods to reduce B-helper T-cells to treat autoimmune diseases
    Baylor Research Institute 2341934*

  • Methods for improvement of beta cell function
    XOMA Technology 2341935*

  • Methods for treating or preventing IL-1beta related diseases
    XOMA Technology 2341936*

  • Compsn for treating disease
    Biotest 2341937*

  • Use of an ANG-(1-7) receptor agonist in acute lung injury
    Charité - Universitätsmedizin Berlin 2341938*

You may also like